Recent:Krishnan.
Convalescent Plasma has been officially adopted
in 1 country.
Submit updates/corrections .
Jun 10 |
et al., Value in Health, doi:10.1016/j.jval.2023.03.2056 | Variation in Demographic Characteristics, Socioeconomic Status, Clinical Presentation and Selected Treatments in Mortality Among Patients with a Diagnosis of COVID-19 in the United States |
| Retrospective analysis of mortality for COVID-19 patients in the USA. Authors do not provide adjusted results, preventing any strong evidence. However it is notable that, despite comparable treatment frequencies, the mortality for patient.. | ||
Apr 5 |
et al., The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.22-0705 | Predictors of Mortality among Patients Hospitalized with COVID-19 during the First Wave in India: A Multisite Case-Control Study |
| 270% higher mortality (p=0.07). Case control study with 2,431 hospitalized COVID-19 patients in India, showing higher mortality with convalescent plasma treatment, without statistical significance. | ||
Feb 15 |
et al., Saudi Pharmaceutical Journal, doi:10.1016/j.jsps.2023.02.004 | Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study |
| 14% higher mortality (p=0.39), 17% higher progression (p=0.05), 43% longer ICU admission (p=0.003), and 32% longer hospitalization (p=0.01). PSM retrospective 29 hospitals in Saudi Arabia, showing longer ICU and hospitalization time with convalescent plasma, but no significant difference in mortality. | ||
Jan 31 |
et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiad023 | Symptom duration and resolution with early outpatient treatment of convalescent plasma for COVID- 19: a randomized trial |
| 1% worse recovery (p=0.62). RCT 1,070 outpatients in the USA, showing no significant difference in recovery with convalescent plasma treatment. | ||
Dec 29 2022 |
et al., Nature Cancer, doi:10.1038/s43018-022-00503-w | Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial |
| 8% lower mortality (p=0.39), 2% higher ventilation (p=1), and 22% improved 7-point scale results (p=0.22). RCT 134 hospitalized patients showing no significant difference in outcomes with convalescent plasma for all patients, however significantly improved mortality and time to improvement was seen for patients with cancer. | ||
Dec 16 2022 |
et al., JAMA, doi:10.1001/jama.2022.23257 | Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial |
| 1% lower mortality (p=0.9). Long-term followup for the REMAP-CAP very late stage ICU trial, showing no significant difference with convalescent plasma treatment. | ||
Nov 30 2022 |
et al., Chest, doi:10.1016/j.chest.2022.06.029 | Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19 |
| 3% higher mortality (p=0.86) and 4% worse 7-point scale results (p=0.76). RCT 947 hospitalized patients in the USA, showing no signficant difference with convalescent plasma treatment. | ||
Sep 30 2022 |
et al., Scientific Reports, doi:10.1038/s41598-022-19629-z | A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia |
| 76% higher mortality (p=0.43), 31% higher ICU admission (p=0.77), and 41% worse 7-point scale results (p=0.32). RCT 147 patients in Denmark, showing no significant difference in outcomes with convalescent plasma. The trial was terminated due to futility. | ||
Aug 26 2022 |
et al., medRxiv, doi:10.1101/2022.08.25.22279181 | International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship |
| 240% higher mortality (p<0.0001). Retrospective 3,966 COVID-19 patients, 1,115 with cancer, showing lower mortality with remdesivir and higher mortality with convalescent plasma. | ||
Aug 23 2022 |
et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2022.08.005 | Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial |
| 14% lower progression (p=0.42), 39% lower hospitalization (p=0.22), and 1% worse recovery (p=0.92). RCT 416 outpatients in the Netherlands, showing no significant difference with convalesent plasma treatment. Hospitalization was lower, and improved results were seen with ≤5 days of symptoms, without statistical significance. | ||
Aug 10 2022 |
et al., medRxiv, doi:10.1101/2022.08.09.22278329 | COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency |
| 49% lower mortality (p=0.16), 68% higher progression (p=0.18), and 7% longer hospitalization (p=0.99). RCT 120 hospitalized patients in France, showing no significant difference in outcomes with convalescent plasma treatment, with the exception of lower mortality in the subgroup of immunosuppressed patients. | ||
Jun 30 2022 |
et al., The Lancet Regional Health - Americas, doi:10.1016/j.lana.2022.100216 | Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI) |
| 52% higher mortality (p=0.37). RCT 129 severe COVID-19 patients in Brazil, showing no significant difference in outcomes with convalescent plasma. | ||
Jun 27 2022 |
et al., BMC Infectious Diseases, doi:10.1186/s12879-022-07560-7 | Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study |
| 220% higher mortality (p=0.16), 38% higher hospital discharge (p=0.04), and 25% worse viral clearance (p=0.72). RCT 91 hospitalized patients in Colombia showing shorter time to discharge with convalescent plasma, but higher mortality (without statistical significance). | ||
Mar 31 2022 |
et al., Emerging Infectious Diseases, doi:10.3201/eid2803.212299 | High-Dose Convalescent Plasma for Treatment of Severe COVID-19 |
| 13% lower mortality (p=0.67). RCT 110 hospitalized patients in Brazil, showing no significant difference in outcomes with high-dose convalescent plasma. | ||
Feb 15 2022 |
et al., Scientific Reports, doi:10.1038/s41598-022-06221-8 | Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial) |
| 17% lower mortality (p=0.65), 67% lower ventilation (p=0.36), 5% greater improvement (p=1), and 3% lower hospital discharge (p=1). RCT 103 hospitalized patients in South Africa, showing no significant difference in outcomes with convalescent plasma. | ||
Feb 9 2022 |
et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00545-2 | High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial |
| 80% lower mortality (p=0.5), 5% higher hospitalization (p=1), 5% worse recovery (p=0.67), and 4% worse viral clearance (p=0.33). RCT 188 convalescent plasma and 188 control patients, showing no significant difference in outcomes. | ||
Jan 9 2022 |
et al., Transfusion Medicine, doi:10.1111/tme.12851 | Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection |
| 12% lower mortality (p=1). RCT 158 patients in Ecuador, showing no significant difference in mortality with convalescent plasma. Authors note indications of improved results for earlier treatment. | ||
Jan 1 2022 |
et al., Tanaffos 21:1 | Effect of Convalescent Plasma Therapy on Clinical Improvement of COVID-19 Patients: A Randomized Clinical Trial |
| 45% higher mortality (p=0.38), 8% higher ICU admission (p=0.85), 250% higher ARDS (p=0.16), and 10% longer hospitalization (p=0.39). RCT 120 hospitalized patients in Iran, showing no significant differences with convalescent plasma treatment. | ||
Dec 21 2021 |
et al., New England Journal of Medicine, doi:10.1056/NEJMoa2119657 (date from preprint) | Early Outpatient Treatment for Covid-19 with Convalescent Plasma |
| 86% lower mortality (p=0.12) and 54% lower hospitalization (p=0.005). RCT 1,181 outpatients in the USA, mean 6 days from symptom onset, showing lower hospitalization with treatment. NCT04373460. | ||
Dec 15 2021 |
et al., Journal of Clinical Investigation, doi:10.1172/JCI155114 | A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia |
| 81% lower mortality (p=0.03), 44% greater improvement (p=0.18), and 51% lower ventilation (p=0.16). RCT 79 hospitalized patients in the USA, showing significant benefit in clinical severity score and 28-day mortality with convalescent plasma treatment. | ||
Dec 13 2021 |
et al., JAMA Internal Medicine, doi:10.1001/jamainternmed.2021.6850 | Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients |
| 12% lower mortality (p=0.45) and 8% improved 7-point scale results (p=0.5). RCT 941 hospitalized patients in the USA, showing no significant difference with convalescent plasma treatment. | ||
Dec 4 2021 |
et al., BMC Research Notes, doi:10.1186/s13104-021-05847-7 | Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden |
| 19% lower progression (p=1), 57% higher need for oxygen therapy (p=0.43), and 62% longer hospitalization (p=0.21). RCT 31 hospitalized patients requiring supplemental oxygen in Sweden, showing no significant difference in outcomes with convalescent plasma. | ||
Nov 29 2021 |
et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.36246 | Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia |
| 23% lower mortality (p=0.47), 4% higher ventilation (p=1), and 12% lower progression (p=0.54). RCT 487 patients in Italy, showing no significant difference in outcomes with convalescent plasma. | ||
Oct 15 2021 |
et al., Journal of Clinical Investigation, doi:10.1172/JCI152264 | Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19 |
| 37% lower mortality (p=0.19) and 16% improved recovery (p=0.32). RCT 105 hospitalized patients in Germany, 53 treated with convalescent plasma, showing no significant difference in mortality or the primary composite outcome of survival and no longer fulfilling criteria for severe COVID-19 on day 21. | ||
Sep 9 2021 |
et al., Nature Medicine, doi:10.1038/s41591-021-01488-2 | Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial |
| 13% higher mortality (p=0.33) and 16% higher combined mortality/intubation (p=0.18). RCT 940 hospitalized patients, 614 assigned to convalescent plasma, showing no significant differences. | ||
Aug 26 2021 |
et al., European Respiratory Journal, doi:10.1183/13993003.01724-2021 | Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma |
| 1% lower mortality (p=0.98), 8% higher ventilation (p=0.78), and no change in ICU admission (p=1). RCT 489 hospitalized COVID-19 patients in Belgium, showing no significant difference in outcomes with convalescent plasma. | ||
Aug 23 2021 |
et al., NCT04421404 | Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients (CAPRI) |
| 425% higher ventilation (p=0.21) and 425% higher progression (p=0.21). RCT 34 hospitalized patients in the USA, showing no significant difference with convalescent plasma treatment. | ||
Aug 18 2021 |
et al., NEJM, doi:10.1056/NEJMoa2103784 | Early Convalescent Plasma for High-Risk Outpatients with Covid-19 |
| 396% higher mortality (p=0.22), 10% lower hospitalization (p=0.59), and 6% lower progression (p=0.7). RCT 511 emergency department patients, 257 assigned to convalescent plasma, showing no significant difference in outcomes. | ||
Aug 9 2021 |
et al., BMJ Open Respiratory Research, doi:10.1136/bmjresp-2021-001017 | Efficacy of convalescent plasma for treatment of COVID-19 in Uganda |
| 21% higher mortality (p=0.8), 9% lower progression (p=1), no change in recovery (p=0.77), and 50% slower viral clearance (p=0.2). RCT 136 hospitalized COVID-19 patients in Uganda, showing no significant benefit with convalescent plasma treatment. | ||
Jul 8 2021 |
et al., European Respiratory Journal, doi:10.1183/13993003.01471-2021 | Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial |
| 38% higher mortality (p=0.42), 11% worse improvement (p=0.74), and 67% longer hospitalization (p=0.87). RCT 160 hospitalized patients in Brazil, showing no significant difference in outcomes with convalescent plasma. | ||
May 27 2021 |
et al., Nature Communications, doi:10.1038/s41467-021-23469-2 | Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection |
| 4% lower mortality (p=0.95) and 12% higher hospital discharge (p=0.68). RCT 86 hospitalized patients, 43 treated with convalescent plasma, showing no significant differences with treatment. Authors conclude that the most likely explanation was already high antibody titers on the day of inclusion, and they rec.. | ||
Apr 16 2021 |
et al., Critical Care Medicine, doi:10.1097/CCM.0000000000005066 | Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York |
| 19% lower mortality (p=0.75) and no change in improvement (p=1). RCT 74 hospitalized patients in the USA, showing no significant difference with convalescent plasma treatment. | ||
Apr 10 2021 |
et al., Internal and Emergency Medicine, doi:10.1007/s11739-021-02734-8 | A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm |
| 30% longer hospitalization (p=0.06). RCT 62 hospitalized patients in Iran, showing no significant difference in mortality and length of stay with convalescent plasma. | ||
Mar 31 2021 |
et al., medRxiv, doi:10.1101/2021.03.28.21254507 | Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial |
| 7% higher mortality (p=0.76). RCT 190 hospitalized severe condition patients in Mexico, showing no significant difference between convalescent plasma and human immunoglobulin treatment. | ||
Mar 3 2021 |
et al., PLOS Medicine, doi:10.1371/journal.pmed.1003415 | Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial |
| 247% higher mortality (p=0.17), 163% higher ventilation (p=0.22), and 23% higher progression (p=0.51). Small RCT with 28 early and 30 deferred (treated according to prespecified deterioration criteria) convalescent plasma patients, not showing significant differences. "Early" is relative, with a median of 5 days from symptom onse.. | ||
Jan 15 2021 |
, The Lancet, doi:10.1016/S0140-6736(21)00897-7 (press release 1/15/2021) | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial |
| no change in mortality (p=0.95) and 1% lower hospital discharge (p=0.57). RCT 16,287 hospitalized patients in the UK, showing no significant differences with convalescent plasma treatment. Subgroup analysis shows better results for those treated <= 7 days from symptom onset. | ||
Jan 6 2021 |
et al., NEJM, doi:10.1056/NEJMoa2033700 | Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults |
| 67% lower ICU admission (p=0.17) and 48% lower progression (p=0.03). RCT 160 patients >=65 with symptom onset <72 hours, 80 treated with convalescent plasma, showing lower progression to severe disease with treatment. | ||
Nov 29 2020 |
et al., medRxiv, doi:10.1101/2020.11.25.20237883 | Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial |
| 33% lower mortality (p=0.34). Small RCT 80 hospitalized patients in India, 40 treated with convalescent plasma, not showing significant differences in primary analysis. Authors note that significant improvement in hypoxia, reduction in hospital stay, and survival bene.. | ||
Nov 24 2020 |
et al., NEJM, doi:0.1056/NEJMoa2031304 | A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia |
| 4% lower mortality (p=1) and 19% improved 7-point scale results (p=0.4). RCT 333 hospitalized patients in Argentina, 228 treated with convalescent plasma, showing no significant differences in clinical status or mortality. | ||
Nov 4 2020 |
et al., Scientific Reports, doi:10.1038/s41598-021-89444-5 (date from preprint) | Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease |
| 33% lower ventilation (p=0.47) and 22% shorter hospitalization (p=0.12). Small RCT with 40 hospitalized patients in Bahrain, 20 treated with convalescent plasma, not showing significant differences. NCT04356534. | ||
Oct 27 2020 |
et al., medRxiv, doi:10.1101/2020.10.25.20219337 | Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial |
| 323% higher mortality (p=0.22), 221% higher ventilation (p=0.33), 25% shorter hospitalization (p=0.08), and 32% improved viral clearance (p=0.11). Small RCT 29 patients in India, 14 treated with convalescent plasma, not showing significant differences with treatment. | ||
Oct 22 2020 |
et al., BMJ, doi:10.1136/bmj.m3939 | Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) |
| 7% higher mortality (p=0.74), 7% higher progression (p=0.74), 1% lower ventilation (p=0.98), and 28% improved viral clearance (p=0.02). RCT 464 hospitalized patients in India, 235 treated with convalescent plasma, showing no improvement in combined death at 28 days or progression to severe disease. | ||
Sep 29 2020 |
et al., medRxiv, doi:10.1101/2020.08.26.20182444 | Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial |
| 88% lower mortality (p=0.12) and 93% lower progression (p=0.01). Early terminated RCT with 81 hospitalized patients, 38 treated with convalescent plasma, showing lower progression with treatment. NCT04345523. | ||
Jun 3 2020 |
et al., JAMA, doi:10.1001/jama.2020.10044 | Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial |
| 35% lower mortality (p=0.3), 15% greater improvement (p=0.37), and 76% improved viral clearance (p=0.01). Small RCT 103 severe condition patients, 52 treated with convalescent plasma, showing improved viral clearance but no statistically significant improvements in mortality or clinical improvement. ChiCTR2000029757. | ||
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.